Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

11,818 recalls · Class II, newest first

Class II · Moderate risk

Avastin

Lack of Assurance of Sterility; product linked to adverse event reports of endophthalimitis eye infections and FDA inspection findings resulted in concerns regarding quality control processes

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-918-2013
Class II · Moderate risk

Oxiracetam & Choline

Marketed Without an Approved NDA/ANDA: The products are unapproved drugs

Terminated Unapproved drug Palmer Natural Products D-236-2013
Class II · Moderate risk

BoostYourGrade.com

Marketed Without an Approved NDA/ANDA: The products are unapproved drugs

Terminated Unapproved drug Palmer Natural Products D-235-2013
Class II · Moderate risk

Brain Defogger

Marketed Without an Approved NDA/ANDA: The products are unapproved drugs

Terminated Unapproved drug Palmer Natural Products D-234-2013
Class II · Moderate risk

Piracetam & Choline

Marketed Without an Approved NDA/ANDA: The products are unapproved drugs

Terminated Unapproved drug Palmer Natural Products D-233-2013
Class II · Moderate risk

Aniracetam and Choline

Marketed Without an Approved NDA/ANDA: The products are unapproved drugs

Terminated Unapproved drug Palmer Natural Products D-232-2013
Class II · Moderate risk

Rifadin

Subpotent drug: low fill volume in some of the capsules

Terminated Wrong potency / content Sanofi US NDC 0068-0510-30 D-841-2013
Class II · Moderate risk

Venlafaxine Hydrochloride Tablets

Failed Tablet/Capsule Specifications: Pharmacist complaint of an excessive amount of broken and/or chipped tablets in the bottle.

Terminated Failed specification Zydus Pharmaceuticals USA Inc NDC 68382-021-01 D-202-2013
Class II · Moderate risk

FREPP/SEPP Kit containing 1 FREPP

Labeling: Not Elsewhere Classified: This product is misbranded because the product is not sterile and the labeling is misleading in relation to sterility claims.

Terminated Labeling / mix-up CareFusion 213, LLC NDC 54365-202-99 D-229-2013
Class II · Moderate risk

Donor Prep Kit containing 1 FREPP

Labeling: Not Elsewhere Classified: This product is misbranded because the product is not sterile and the labeling is misleading in relation to sterility claims.

Terminated Labeling / mix-up CareFusion 213, LLC NDC 54365-201-99 D-228-2013
Class II · Moderate risk

Blood Culture Prep Kit II containing 1 FREPP

Labeling: Not Elsewhere Classified: This product is misbranded because the product is not sterile and the labeling is misleading in relation to sterility claims.

Terminated Labeling / mix-up CareFusion 213, LLC NDC 54365-200-99 D-227-2013
Class II · Moderate risk

SEPP 10% Povidone Iodine Solution USP

Labeling: Not Elsewhere Classified: This product is misbranded because the product is not sterile and the labeling is misleading in relation to sterility claims.

Terminated Labeling / mix-up CareFusion 213, LLC NDC 54365-145-01 D-226-2013
Class II · Moderate risk

SEPP 2% Iodine Tincture USP

Labeling: Not Elsewhere Classified: This product is misbranded because the product is not sterile and the labeling is misleading in relation to sterility claims.

Terminated Labeling / mix-up CareFusion 213, LLC NDC 54365-161-01 D-225-2013
Class II · Moderate risk

SEPP 70% Isopropanol

Labeling: Not Elsewhere Classified: This product is misbranded because the product is not sterile and the labeling is misleading in relation to sterility claims.

Terminated Labeling / mix-up CareFusion 213, LLC NDC 54365-170-01 D-224-2013
Class II · Moderate risk

0.9% Sodium Chloride Injection

Labeling Wrong Barcode; It may display wrong product code reflecting 0.9% Sodium Chloride Injection , USP 100 mL in MINI-BAG Plus container instead of 50 mL.

Terminated Labeling / mix-up Baxter Healthcare Corp. NDC 0338-0553-11 D-623-2013
Class II · Moderate risk

Rifadin (rifampin)

Subpotent Drug: During review of retain samples, the manufacturer observed low fill in some capsules, which was related to an issue detected with the encapsulating equipment.

Terminated Wrong potency / content Sanofi-Synthelabo D-886-2013
Class II · Moderate risk

Cefdinir for Oral Suspension

Defective Container: This recall is being carried out due to the potential for improperly sealed bottles.

Terminated Packaging defect Teva Pharmaceuticals USA, Inc. NDC 0093-4136-64 D-247-2013

Recalls by year